Status:
COMPLETED
Study of AEE788 in Patients With Recurrent/Relapse Glioblastoma Multiforme (GBM)
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Glioblastoma Multiforme
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
AEE788 is an orally active, reversible, small-molecule, multi-targeted kinase inhibitor with potent inhibitory activity against the ErbB and VEGF receptor family of tyrosine kinases. It has an IC50 of...
Eligibility Criteria
Inclusion
- Histologically confirmed GBM in first or second recurrence or relapse
- Adequate hematologic, hepatic and renal function
- Age ≥ 18 years
- Karnofsky performance status score ≥ 70%
- Life expectancy ≥ 12 weeks
Exclusion
- Peripheral neuropathy \> grade 1
- Diarrhea \> grade 1
- Gastrointestinal dysfunction
- Compromised cardiac function
- Concurrent severe and/or uncontrolled medical conditions
Key Trial Info
Start Date :
January 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2005
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT00116376
Start Date
January 1 2004
End Date
November 1 2005
Last Update
November 10 2015
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California at Los Angeles
Los Angeles, California, United States, 90095
2
University of California, San Francisco
San Francisco, California, United States, 94143
3
The Brain Tumor Center at Duke, Duke University Medical Center
Box 3624 Dumc, Trent Drive, Durham, North Carolina, United States, 27710
4
University of Texas, MD Anderson Cancer Center
Houston, Texas, United States, 77030